Disagree
Home Livewell Pharmaceuticals Livewell Pharmaceuticals
Ipamorelin
Ipamorelin - Livewell Pharmaceuticals

Ipamorelin - Livewell Pharmaceuticals

Brand:
Category:
Substance:
Package:
2 mg
Price:
€61.00 - €61.00
See options
Product Overview
Ipamorelin is a potent GH secretagogue that binds GHSR-1a, stimulating GH release and promoting anabolic effects. Studies indicate it enhances gastric motility in postoperative ileus and increases body fat in GH-deficient and normal mice. Unlike GH, ipamorelin does not cause liver enlargement, making it a safer alternative. It boosts serum leptin and appetite early in treatment and may aid in managing hypogonadism-related obesity. Though human data are limited, ipamorelin’s favorable profile highlights its therapeutic potential in metabolic and hormonal disorders.
References:

Sinha, D.K., Balasubramanian, A., Tatem, A.J., Rivera-Mirabal, J., Yu, J., Kovac, J., Pastuszak, A.W. and Lipshultz, L.I., 2020. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology. 

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Ipamorelin by Livewell Pharmaceuticals, consult with your doctor or healthcare professional.

Products
Show more
FAQ
What body composition effects does ipamorelin have in GH-deficient mice?
It increased body weight and fat mass, with weight gain stabilizing after 1–2 weeks.
References:

Sinha, D.K., Balasubramanian, A., Tatem, A.J., Rivera-Mirabal, J., Yu, J., Kovac, J., Pastuszak, A.W. and Lipshultz, L.I., 2020. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology. 

How does ipamorelin compare to GH in terms of adiposity?
Ipamorelin increased fat pad weight and leptin levels, while GH decreased fat mass.
References:

Sinha, D.K., Balasubramanian, A., Tatem, A.J., Rivera-Mirabal, J., Yu, J., Kovac, J., Pastuszak, A.W. and Lipshultz, L.I., 2020. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology. 

What were the findings of human POI clinical trials?
Though not statistically significant, ipamorelin showed trends toward faster GI recovery after open surgery.
References:

Sinha, D.K., Balasubramanian, A., Tatem, A.J., Rivera-Mirabal, J., Yu, J., Kovac, J., Pastuszak, A.W. and Lipshultz, L.I., 2020. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology.